Pancreatic cancer: From molecular signature to target therapy
Authors:
- F. CacciamaniFCF. Cacciamani
- G. NasoGNG. Naso
- G. GaspariniGGG. Gasparini
- 1 December 2008
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 68 (3) , 197-211
Abstract
No abstract availableKeywords
This publication has 89 references indexed in Scilit:
- Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancerBritish Journal of Cancer, 2006
- Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic CancerJournal of Clinical Oncology, 2005
- Celecoxib and cardiovascular risksExpert Opinion on Drug Safety, 2005
- Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinomaCancer, 2004
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Targeting HIF-1 for cancer therapyNature Reviews Cancer, 2003
- Clinicopathological significance of hypoxia‐inducible factor‐1α expression in human pancreatic carcinomaHistopathology, 2003
- Epidermal growth factor receptor-targeted therapy for pancreatic cancerSeminars in Oncology, 2002
- New applications of gemcitabine and future directions in the management of pancreatic cancerCancer, 2002
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987